The goal ofthis clinical core is to provide high numbers of samples of PBMC from subjects with acute / early phase HCV infecfion, allowing large-scale studies of immunologic parameters for investigators throughout the collaborative center. Funding of this core would allow continued identification of acute / early stage HCV infection in the Massachusetts State Prison system. Rationale includes the high number of young injection drug users entering the prison systems yearty, who are therefore at risk for HCV infection. The identification of acute HCV had traditionally been reliant on symptoms or laboratory abnormalities rather than exposure history, but our prior funding period established a system based on history-based risk factors to screen for early-stage HCV infecfion. This brief 1-2 minute quesfionnaire was designed to assist providers in identifying persons at nsk for recent acquisition of HCV by injection drug use. The successful implementation in the MA state prison system identified a large number () of persons with acute HCV over a short period of time. In addition, longitudinal sample acquisifion was greafiy enhanced by this project. This represents the first systematic study of acute HCV among persons entering the prison system, providing critical information regarding the overall prevalence, clinical characteristics, and treatment outcomes of acute HCV in incarcerated individuals. Funding from this clinical core would allow continuafion ofthis unique and valuable resource for both members ofthis Collaborative Center as well as allow collaboration with other groups examining questions not being addressed directly by this grant.
This core is complementary to the Brazilian cohort, insofar that it provides samples from injection drug users, whose immunologic parameters may differ in key aspects from those with other modes of acquisition of HCV. The high quality of the samples and ability to obtain longitudinal samples is also relevant and critical to the success of the other projects contained within this application.
|Yu, Wen-Han; Cosgrove, Cormac; Berger, Christoph T et al. (2018) ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection. Pathog Immun 3:2-18|
|Forconi, Catherine S; Cosgrove, Cormac P; Saikumar-Lakshmi, Pryia et al. (2018) Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas. Blood Adv 2:1101-1114|
|Torres-Cornejo, Almudena; Lauer, Georg M (2017) Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2:102-125|
|Vergara, C; Thio, C; Latanich, R et al. (2017) Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun 18:82-87|
|Wolski, David; Foote, Peter K; Chen, Diana Y et al. (2017) Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. Immunity 47:648-663.e8|
|Rodrigo, Chaturaka; Walker, Melanie R; Leung, Preston et al. (2017) Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol 49:88-96|
|Rodrigo, C; Eltahla, A A; Bull, R A et al. (2017) Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study. J Viral Hepat 24:43-52|
|Rodrigo, Chaturaka; Eltahla, Auda A; Bull, Rowena A et al. (2016) Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 214:1383-1389|
|Page, Kimberly; Mirzazadeh, Ali; Rice, Thomas M et al. (2016) Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infect Dis 3:ofw024|
|Gunn, Bronwyn; Schneider, Jeffrey; Shansab, Maryam et al. (2016) Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol 9:1549-1558|
Showing the most recent 10 out of 57 publications